氟尿嘧啶与剂量密集辅助化疗在早期乳腺癌患者中的研究(GIM2):一项随机3期试验的研究结束结果
GIM2研究纳入2091例淋巴结阳性早期乳腺癌患者,2×2析因设计比较FEC-P与EC-P方案及剂量密集与标准间隔化疗。中位随访15.1年,FEC-P与EC-P的无病生存无显著差异(HR 1.12,P=0.11),剂量密集组无病生存显著优于标准间隔组(HR 0.77,P=0.0004)。
要点
- 在淋巴结阳性早期乳腺癌中,辅助化疗加入氟尿嘧啶未显著改善无病生存(HR 1.12,P=0.11)。
- 剂量密集方案较标准间隔方案显著改善无病生存(HR 0.77,P=0.0004)。
- 延长随访期间未报告新的3-4级不良事件或毒性相关死亡。
核心结论
- GIM2研究更新结果支持高危早期乳腺癌的最佳辅助化疗不应包含氟尿嘧啶,且应采用剂量密集方案。
研究设计与样本
- GIM2是一项2×2析因、开放标签、随机3期试验,在意大利81家医院入组18-70岁、体能状态ECOG 0-1、可手术的淋巴结阳性乳腺癌患者。
- 患者按1:1:1:1随机分配至q3EC-P组、q3FEC-P组、q2EC-P组或q2FEC-P组,随机化按中心分层、区组大小为12,通过中央交互式互联网系统进行。
- 主要终点为意向治疗人群的无病生存,比较不同化疗间隔(剂量密集 vs 标准间隔)和方案(FEC-P vs EC-P)。
- 2003年4月24日至2006年7月3日共随机分配2091例患者:q3EC-P组545例、q3FEC-P组544例、q2EC-P组502例、q2FEC-P组500例。
- EC-P vs FEC-P的意向治疗分析纳入2091例(EC-P组1047例 vs FEC-P组1044例);剂量密集 vs 标准间隔的意向治疗分析纳入2003例(剂量密集组1002例 vs 标准间隔组1001例)。
主要发现
- 中位随访15.1年(IQR 8.4-16.3),FEC-P组与EC-P组的中位无病生存无显著差异(17.09年[95%CI 15.51-未达到] vs 未达到[17.54-未达到];未校正HR 1.12[95%CI 0.98-1.29];log-rank P=0.11)。
- 剂量密集组的中位无病生存显著高于标准间隔组(未达到[95%CI 17.45-未达到] vs 16.52年[14.24-17.54];HR 0.77[95%CI 0.67-0.89];P=0.0004)。
- 最常见的3-4级不良事件为中性粒细胞减少(q3EC-P组200/536例[37%] vs q3FEC-P组257/533例[48%] vs q2EC-P组50/496例[10%] vs q2FEC-P组97/492例[20%])和脱发(238例[44%] vs 249例[47%] vs 228例[46%] vs 235例[48%])。
- 延长随访期间未报告新的3-4级不良事件或毒性相关死亡。
- 治疗相关严重不良事件发生率:q3EC-P组9例(2%)、q3FEC-P组7例(1%)、q2EC-P组9例(2%)、q2FEC-P组9例(2%);无治疗相关死亡。
关键数值与推荐
- q3EC-P方案:表柔比星90 mg/m²和环磷酰胺600 mg/m²第1天静脉给药,每3周一次,共4周期,随后紫杉醇175 mg/m²第1天静脉给药,每3周一次,共4周期。
- q3FEC-P方案:氟尿嘧啶600 mg/m²、表柔比星90 mg/m²和环磷酰胺600 mg/m²第1天静脉给药,每3周一次,共4周期,随后紫杉醇175 mg/m²第1天静脉给药,每3周一次,共4周期。
- q2EC-P方案:药物及剂量同q3EC-P组,但每2周给药一次。
- q2FEC-P方案:药物及剂量同q3FEC-P组,但每2周给药一次。
临床怎么用
- GIM2研究更新结果支持高危早期乳腺癌的最佳辅助化疗不应包含氟尿嘧啶,且应采用剂量密集方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous analyses of the GIM (Gruppo Italiano Mammella) 2 study showed that addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel in patients with node-positive early breast cancer does not improve outcome, whereas dose-dense chemotherapy induces a significant improvement in both disease-free survival and overall survival as compared with a standard schedule. Here, we present long-term results of the study. METHODS: In this 2 × 2 factorial, open-label, randomised, phase 3 trial, we enrolled patients aged 18-70 years with operable, node-positive, breast cancer with Eastern Cooperative Oncology Group performance status of 0-1 from 81 hospitals in Italy. Eligible patients were randomly allocated (1:1:1:1) to one of the four following study groups: four cycles of standard-interval intravenous EC (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2) on day 1 every 3 weeks, followed by four cycles of intravenous paclitaxel (175 mg/m2) on day 1 every 3 weeks (q3EC-P group); four cycles of intravenous FEC (fluorouracil 600 mg/m2, epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2) on day 1 every 3 weeks, followed by four cycles of intravenous paclitaxel (175 mg/m2) on day 1 every 3 weeks (q3FEC-P group); dose-dense EC-P regimen, with the same doses and drugs as the q3EC-P group but administered every 2 weeks (q2EC-P group); and the dose-dense FEC-P regimen, with the same doses and drugs as the q3FEC-P group but given every 2 weeks (q2FEC-P). Randomisation, with stratification by centre, with permuted blocks of size 12, was done with a centralised, interactive, internet-based system that randomly generated the treatment allocation. The primary endpoint was disease-free survival in the intention-to-treat population, comparing different chemotherapy schedule (dose-dense vs standard-dose intervals) and regimen (FEC-P vs EC-P). Safety population included all patients that received at least one dose of any study drug according to the treatment received. This trial is registered with ClinicalTrials.gov, NCT00433420, and is now closed. FINDINGS: Between April 24, 2003, and July 3, 2006, 2091 patients were randomly assigned to treatment: 545 to q3EC-P, 544 to q3FEC-P, 502 to q2EC-P, and 500 to q2FEC-P. 88 patients were enrolled in centres providing only standard interval schedule and were assigned only to q3FEC-P and q3EC-P; thus, 2091 patients were included in the intention-to-treat analysis for the comparison of EC-P (1047 patients) versus FEC-P (1044 patients) and 2003 patients were included in the intention-to-treat analysis for the comparison of dose-dense (1002 patients) versus standard interval analysis (1001 patients). After a median follow-up of 15·1 years (IQR 8·4-16·3), median disease-free survival was not significantly different between FEC-P and EC-P groups (17·09 years [95% CI 15·51-not reached] vs not reached [17·54-not reached]; unadjusted hazard ratio 1·12 [95% CI 0·98-1·29]; log-rank p=0·11). Median disease-free survival was significantly higher in the dose-dense interval group than the standard-interval group (not reached [95% CI 17·45-not reached] vs 16·52 [14·24-17·54]; 0·77 [95% CI 0·67-0·89]; p=0·0004). The most common grade 3-4 adverse events were neutropenia (200 [37%] of 536 patients in the q3EC-P group vs 257 [48%] of 533 in the q3FEC-P group vs 50 [10%] of 496 q2EC-P vs 97 [20%] of 492) and alopecia (238 [44%] vs 249 [47%] vs 228 [46%] vs 235 [48%]). During extended follow-up, no further grade 3-4 adverse events or deaths related to toxic-effects were reported. Treatment-related serious adverse events were reported in nine (2%) patients in the q3EC-P group, seven (1%) in the q3FEC-P group, nine (2%) in the q2EC-P group, and nine (2%) in the q2FEC-P group. No treatment-related deaths occurred. INTERPRETATION: Updated results from the GIM2 study support that optimal adjuvant chemotherapy for patients with high-risk early breast cancer should not include fluorouracil and should use a dose-dense schedule. FUNDING: Bristol-Myers Squibb, Pharmacia, Dompè Biotec Italy, Italian Ministry of Health, Fondazione Italiana per la Ricerca sul Cancro, and Alliance Against Cancer.
引用
- Del Mastro L, Poggio F, Blondeaux E, et al. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Lancet Oncol. 2022. PMID: 36370716. doi:10.1016/S1470-2045(22)00632-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。